Latest kidney cancer Stories
According to a new study, men employed in occupations with potential exposure to high levels of sunlight have a reduced risk of kidney cancer compared with men who were less likely to be exposed to sunlight at work.
Physicians who conducted a pilot study at UNC Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug sorafenib can reduce the size of large tumors and could be safely undertaken administered without adding significantly to the risks of surgery.
Researchers are able to predict and reverse resistance to a commonly used treatment.
Being obese could lead to a greater risk of developing the most common form of renal cell cancer, according to research in the January issue of the UK-based urology journal BJUI.
In a new study, scientists have searched for mutations in the gene regions of more than 100 kidney cancer samples, the largest number of samples from a single tumor type to be sequenced to date.
The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma.
SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S.
PHILADELPHIA, Oct. 5 /PRNewswire/ -- GlaxoSmithKline [NYSE: GSK] today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib).
FRIMLEY, England, September 25 /PRNewswire/ -- - This Press Release is Intended for Consumer Media Only - Afinitor More Than Doubles the Median Time Without Tumour Growth and Reduces the Risk of Disease Worsening or Death by 67% Compared With Placebo (2) - Patients With Advanced Kidney Cancer Have Limited Options Once Tumours Progress After First Line Standard Therapy(3) - Recently Published UK Expert Clinical Consensus Recommend Afinitor as Second-Line...
WAYNE, N.J. and EMERYVILLE, Calif., May 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.